| The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. | |
| | |
MedLine Citation:
|
PMID: 20839896 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Quality of life (QOL) describes an individual's subjective perception of their position in life as evidenced by their physical, psychological and social functioning. Although an established outcome measure in physical health, QOL has more recently become an increasingly important measure in mental health clinical work and research. This article reviews the evidence describing the impact of medications on QOL in attention-deficit hyperactivity disorder (ADHD). Databases were searched for research studies describing the effects of medication on QOL in ADHD: 25 relevant studies were identified. Most (n = 20) of these studies have focused on children and adolescents, and most have investigated a single molecule, atomoxetine (n = 15), with relatively few studies investigating methylphenidate (n = 5), amfetamines (n = 4) and manifaxine (n = 1). These studies support a positive short-term effect of medication on QOL in ADHD for children, adolescents and adults that mirrors, to some extent, the effects of these medications on ADHD symptoms, although with smaller effect sizes. Notwithstanding measurement issues, it will continue to be important that those designing and conducting clinical trials in ADHD, including both pharmacological and non-pharmacological treatments, continue to include measures of QOL as secondary outcome measures. In particular, information about QOL effects in adults and in subjects of all ages taking methylphenidate and amfetamine treatments is urgently needed. The lack of systematic studies of the impact on QOL of psychological therapies, either on their own or in multimodal combinations with medication, is a serious omission that should be urgently addressed. |
| | |
Authors:
|
David Coghill |
Related Documents
:
|
20481646 - Cardiovascular effects of medications for the treatment of attention-deficit hyperactiv... 10654116 - Principles and results of family therapy in schizophrenia. 14663656 - Are patients with schizophrenia under-treated with second-generation antipsychotics? a ... 11493286 - Taking neuroleptic medications as the treatment for schizophrenia: a phenomenological s... 14169726 - Newborn attention as affected by medication during labor. 12044026 - Verification of the biological weapons convention: what is needed? |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: CNS drugs Volume: 24 ISSN: 1172-7047 ISO Abbreviation: CNS Drugs Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-15 Completed Date: 2010-12-23 Revised Date: 2011-12-06 |
Medline Journal Info:
|
Nlm Unique ID: 9431220 Medline TA: CNS Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 843-66 Citation Subset: IM |
Affiliation:
|
Centre for Neuroscience, Division of Medical Sciences, University of Dundee, Centre for Child Health, Dundee, UK. d.r.coghill@dundee.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic Uptake Inhibitors
/
therapeutic use* Attention Deficit Disorder with Hyperactivity / drug therapy*, psychology Central Nervous System Stimulants / therapeutic use* Humans Quality of Life* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic Uptake Inhibitors; 0/Central Nervous System Stimulants |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of pramipexole in the management of Parkinson's disease.
Next Document: Flupirtine in pain management: pharmacological properties and clinical use.